Search results for "MedDRA"

showing 8 items of 8 documents

Accumulated safety data of micafungin in therapy and prophylaxis in fungal diseases

2011

To define better the safety profile of micafungin, an analysis of micafungin clinical trial safety data was undertaken.Adverse event data were pooled worldwide from 17 clinical efficacy and safety studies. Adverse events were coded using the Medical Dictionary for Regulatory Activities version 5.0.In the pooled clinical trial data set, 3028 patients received at least one dose of micafungin. The mean age of patients was 41.4 years; with 296 (9.8%) children (16 years) and 387 (12.8%) elderly patients (≥ 65 years). Common underlying conditions were hematopoietic stem cell and other transplantations (26.1%), malignancies (20.8%) and HIV (32.9%). Mean exposure was 18 days for adults and 29 days …

AdultMalemedicine.medical_specialtyAntifungal AgentsTime FactorsAdolescentDatabases FactualNauseaMedDRAEchinocandinsLipopeptidesYoung AdultInternal medicinemedicineHumansPharmacology (medical)ChildAdverse effectAgedAged 80 and overClinical Trials as TopicDose-Response Relationship Drugbusiness.industryAge FactorsMicafunginInfantGeneral MedicineMiddle AgedHypokalemiaSurgeryClinical trialDiarrheaMycosesChild PreschoolMicafunginVomitingFemalemedicine.symptombusinessmedicine.drugExpert Opinion on Drug Safety
researchProduct

ADVERSE EFFECTS OF GONADOTROPINS USED IN INFERTILITY TREATMENT

2019

Introduction: Infertility represents a problem for more and more couples all over the world, including in Romania. Thus, more and more women need to resort to drugs to treat infertility, treatments which are not without adverse reactions (Boivin et al., 2007). Modern therapy brings significant benefits in the treatment of infertility. Despite all the benefits, the controlled ovarian stimulation treatment does not lack the possibility of adverse reactions to the administered drugs.
 Objectives: The aim of this study was to determine the potential adverse reactions experienced by patients during the treatment with gonadotropins followed by assisted conception
 Methods: A study was d…

Infertilityendocrine systemmedicine.medical_specialtybusiness.industryMedDRADrug administrationOcean EngineeringContext (language use)Urofollitropinmedicine.diseaseHuman reproductionInternal medicinemedicineMenotropinbusinessAdverse effectmedicine.drugCBU International Conference Proceedings
researchProduct

Drug-Induced Liver Injury Associated With Antidepressive Psychopharmacotherapy: An Explorative Assessment Based on Quantitative Signal Detection Usin…

2015

Drug-induced liver injury is a major problem of pharmacotherapy and is also frequent with antidepressive psychopharmacotherapy. However, there are only few studies using a consistent methodologic approach to study hepatotoxicity of a larger group of antidepress ants. We performed a quantitative signal detection analysis using data from the Uppsala Monitoring Centre from the WHO that records adverse drug reaction (ADR) data from worldwide sources; we retrieved substance- and country-specific (Australia, France, Germany, Italy, Spain, the United Kingdom, and the United States) ADR data and calculated reporting odds ratios as measures for disproportionality within a case/noncase approach. To a…

medicine.medical_specialtyInternationalityDatabases FactualMedDRAMirtazapineAmineptinePharmacology03 medical and health sciences0302 clinical medicineInternal medicinePharmacovigilancemedicineAgomelatineAdverse Drug Reaction Reporting SystemsHumansPharmacology (medical)030212 general & internal medicinePharmacologybusiness.industryAustraliaOdds ratiomedicine.diseaseAntidepressive AgentsUnited StatesEuropeChemical and Drug Induced Liver InjuryNefazodonebusiness030217 neurology & neurosurgeryAdverse drug reactionmedicine.drugJournal of clinical pharmacology
researchProduct

Antibiotic prophylaxis for the prevention of infective endocarditis for dental procedures is not associated with fatal adverse drug reactions in Fran…

2018

Background One of the major reasons to stop antibiotic prophylaxis (AP) to prevent infective endocarditis (IE) in the United Kingdom but not in the rest of the world was that it would result in more deaths from fatal adverse drug reactions (ADRs) than the number of IE deaths. The main aim of this study was to quantify and describe the ADRs with amoxicillin or clindamycin for IE AP. The second aim was to infer a crude incidence of anaphylaxis associated with amoxicillin for IE AP. Material and Methods The Medical Dictionary for Regulatory Activities (MedDRA) was used to group ADRs for IE AP using the broad Standardized MedDRA Queries “Anaphylactic reaction, Amoxicillin, Clindamycin, Clostrid…

medicine.medical_specialtyDrug-Related Side Effects and Adverse ReactionsMedDRA03 medical and health sciences0302 clinical medicineInternal medicinePharmacovigilanceHumansMedicineEndocarditisAntibiotic prophylaxisGeneral DentistryOral Medicine and PathologyEndocarditisbusiness.industryResearchClindamycinEndocarditis Bacterial030206 dentistryAntibiotic ProphylaxisAmoxicillinClostridium difficilemedicine.disease:CIENCIAS MÉDICAS [UNESCO]3. Good healthOtorhinolaryngologyInfective endocarditisUNESCO::CIENCIAS MÉDICASSurgeryFrancebusinessmedicine.drug
researchProduct

Long-term general and cardiovascular safety of tiotropium/olodaterol in patients with moderate to very severe chronic obstructive pulmonary disease

2016

Abstract Background Long-term safety, particularly cardiovascular safety, is of special interest in maintenance treatment of chronic obstructive pulmonary disease (COPD) with long-acting β 2 -agonists and long-acting muscarinic antagonists, given potential cardiovascular effects. Methods Two 52-week Phase III trials (TONADO ® ) investigated tiotropium/olodaterol (5/5 and 2.5/5 μg) versus tiotropium 2.5, 5 μg and olodaterol 5 μg. In a pre-specified safety analysis, investigator-reported treatment-emergent adverse events (AEs), electrocardiogram and laboratory data were pooled. All serious AE (SAE) reports were reviewed by an independent Adjudication Committee, which assessed whether deaths, …

MalePulmonary and Respiratory Medicinemedicine.medical_specialtyMedDRAComorbidityMuscarinic AntagonistsPulmonary Disease Chronic Obstructive03 medical and health scienceschemistry.chemical_compound0302 clinical medicineDouble-Blind MethodForced Expiratory VolumeInternal medicineAdministration InhalationmedicineHumans030212 general & internal medicineTiotropium BromideAdverse effectAdrenergic beta-2 Receptor AgonistsAgedCOPDbusiness.industryIncidenceIncidence (epidemiology)OlodaterolTiotropium bromideMiddle Agedmedicine.diseaseComorbidityBenzoxazinesBronchodilator AgentsDrug Combinations030228 respiratory systemchemistryCardiovascular DiseasesAnesthesiaFemalebusinessMaceFollow-Up Studiesmedicine.drug
researchProduct

Opportunistic infections in immunosuppressed patients with juvenile idiopathic arthritis: analysis by the Pharmachild Safety Adjudication Committee

2020

Background: To derive a list of opportunistic infections (OI) through the analysis of the juvenile idiopathic arthritis (JIA) patients in the Pharmachild registry by an independent Safety Adjudication Committee (SAC). Methods: The SAC (3 pediatric rheumatologists and 2 pediatric infectious disease specialists) elaborated and approved by consensus a provisional list of OI for use in JIA. Through a 5 step-procedure, all the severe and serious infections, classified as per MedDRA dictionary and retrieved in the Pharmachild registry, were evaluated by the SAC by answering six questions and adjudicated with the agreement of 3/5 specialists. A final evidence-based list of OI resulted by matching …

Malelcsh:Diseases of the musculoskeletal systemBiologic:Paediatrics: 760 [VDP]Artritis infecciosaMedDRAInfants malaltsArthritisSeverity of Illness IndexHospital patientsCohort StudiesPharmacovigilance0302 clinical medicine030212 general & internal medicineRegistriesChildBiologics; Immunosuppressive therapy; Infections; Juvenile idiopathic arthritis; Opportunisticbiologics ; immunosuppressive therapy ; infections ; juvenile idiopathic arthritis ; opportunisticBarneleddgikt3. Good healthImmunosuppressive therapySettore MED/38 - PEDIATRIA GENERALE E SPECIALISTICAAntirheumatic AgentsChild PreschoolCohortPediatric Infectious DiseaseFemaleInfectionResearch Articlemedicine.medical_specialtyTuberculosisjuvenil idiopathic arthritisBiologicsOpportunistic InfectionsInfectionsHerpes Zoster03 medical and health sciencesImmunocompromised HostJuvenile idiopathic arthritiInternal medicinePharmacovigilancemedicineHumansTuberculosisbook030203 arthritis & rheumatologyMalalts hospitalitzatsImmunosupressióbusiness.industrySick childrenJuvenile idiopathic arthritismedicine.diseaseRheumatologyArthritis JuvenileInfectious arthritis:Pediatri: 760 [VDP]Orthopedic surgeryOpportunistiske infeksjonerbook.journalOpportunisticlcsh:RC925-935businessInfeccions oportunistesImmunosuppression
researchProduct

Riociguat treatment in patients with pulmonary arterial hypertension: Final safety data from the EXPERT registry

2021

OBJECTIVE: The soluble guanylate cyclase stimulator riociguat is approved for the treatment of adult patients with pulmonary arterial hypertension (PAH) and inoperable or persistent/recurrent chronic thromboembolic pulmonary hypertension following Phase 3 randomized trials. The EXPosurE Registry RiociguaT in patients with pulmonary hypertension (EXPERT) study was designed to monitor the long-term safety of riociguat in clinical practice. METHODS: EXPERT was an international, multicenter, prospective, uncontrolled, non-interventional cohort study of patients treated with riociguat. Patients were followed for at least 1 year and up to 4 years from enrollment or until 30 days after stopping ri…

Pulmonary and Respiratory Medicinemedicine.medical_specialtyRegistryMedDRAPeripheral edemaClinical practicePulmonary arterial hypertensionRiociguatlaw.inventionPulmonary hypertension03 medical and health sciences0302 clinical medicineRandomized controlled triallawInternal medicinemedicine030212 general & internal medicineAdverse effectHipertensió pulmonarRiociguatbusiness.industrymedicine.diseasePulmonary hypertensionClinical trial030228 respiratory systemPulmonary hemorrhagemedicine.symptomSafetybusinessmedicine.drug
researchProduct

Safety of Topical Non-steroidal Anti-Inflammatory Drugs in Osteoarthritis: Outcomes of a Systematic Review and Meta-Analysis

2019

Objective We aimed to assess the safety of topical non-steroidal anti-inflammatory drugs (NSAIDs) in the management of osteoarthritis (OA) in a systematic review and meta-analysis of randomized, placebo-controlled trials. Methods A comprehensive literature search was undertaken in the MEDLINE, Cochrane Central Register of Controlled Trials (CENTRAL), and Scopus electronic databases. Randomized, double-blind, placebo-controlled, parallel-group trials that assessed adverse events (AEs) with topical NSAIDs in patients with OA were eligible for inclusion. Authors and/or study sponsors were contacted to obtain the full report of AEs. The primary outcomes were overall severe and serious AEs, as w…

medicine.medical_specialtyDICLOFENAC SODIUM GELDiclofenacDrug-Related Side Effects and Adverse ReactionsMedDRAVEHICLE TDT 064MEDLINEOsteoarthritisKNEE OSTEOARTHRITISAdministration CutaneousPlaceboLONG-TERM USE03 medical and health sciencesDOUBLE-BLIND0302 clinical medicinePharmacotherapyInternal medicineOsteoarthritisHumansMedicinePharmacology (medical)030212 general & internal medicineAdverse effectRandomized Controlled Trials as Topicbusiness.industryAnti-Inflammatory Agents Non-SteroidalTRANSFERSOME GELOdds ratiomedicine.diseaseEFFICACYRANDOMIZED CLINICAL-TRIALORAL CELECOXIBTreatment OutcomeMeta-analysisSystematic ReviewGeriatrics and Gerontologybusiness030217 neurology & neurosurgeryTASK-FORCE
researchProduct